<DOC>
	<DOCNO>NCT02205164</DOCNO>
	<brief_summary>The aim present study evaluate addition Aprepitant multiple dose palonosetron IV enhance efficacy multiple dos palonosetron IV alone , prevent CINV AML High risk MDS patient , treat multiple day chemotherapy .</brief_summary>
	<brief_title>Palonosetron Plus Aprepitant Versus Palonosetron Preventing Nausea Vomiting Leukemic Patients</brief_title>
	<detailed_description>This open-label , randomize , comparative , multicenter phase II study patient AML schedule receive multiple day chemotherapy . Patients receive either PALO+APR PALO regimen 1:1 ratio accord computer-generated , random allocation schedule . Below describe detail antiemetic regimen : PALO+APR regimen : oral aprepitant give day 1-3 ( day 1 , 125 mg , day 2-3 , 80 mg 1 hour chemotherapy ) multiple intravenous bolus Palonosetron without dexamethasone , prior administration chemotherapy , start first day treatment . PALO regimen : multiple intravenous bolus Palonosetron without dexamethasone , prior administration chemotherapy , start first day treatment .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Diagnosis Acute Myeloid Leukaemia Highrisk MDS accord IPSS Patient eligible AMLlike induction therapy Candidate multipledays chemotherapy ( minimum 3 day ) Age , equal18 year ECOG 02 Not pregnant nursing Must able complete patient 's diary Provide write informed consent AML HRMDS therapyrelated Active infection require intravenous antibiotic Prior malignancy sit except surgically treat nonmelanoma skin cancer , prostate cancer , superficial cervical cancer , cancer patient diseasefree more/equal 5 year Unacceptable hepatic function ( 2 time upper limit normal liver transaminase ) renal function ( creatinine 1.5 time upper limit normal ) unless diseaserelated Myocardial infarction within past 6 month Psychiatric CNS disorder interfere ability comply study protocol Known hypersensitivity 5HT3 antagonist component CSF involvement Preexisting nausea vomit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>palonosetron</keyword>
	<keyword>aprepitant</keyword>
	<keyword>CINV</keyword>
	<keyword>AML</keyword>
	<keyword>multiple-days</keyword>
</DOC>